

Contents

Contributors

ix

1. Using evasins to target the chemokine network in inflammation

1

Shoumo Bhattacharya and Akane Kawamura

1. Inflammation and disease	2
2. The chemokine network in inflammation	3
3. Evasins: tick proteins targeting the chemokine network	10
4. Outlook: developing evasins as therapeutics	15
5. Appendix	17
Acknowledgments	19
References	20

2. Biological functions and clinical implications of interleukin-34 in inflammatory diseases

39

Yun Ge, Man Huang, Xiao-mei Zhu, and Yong-ming Yao

Abbreviations	40
1. Introduction	40
2. Biological functions of IL-34	44
3. IL-34 in mediated inflammatory response	49
4. Potential role and its significance of IL-34 in inflammatory diseases	49
5. Discussion and outlook	55
Acknowledgments	56
References	56

3. Pattern recognition receptors as potential drug targets in inflammatory disorders

65

Declan P. McKernan

1. Introduction	66
2. Pattern-recognition receptors	67
3. Pharmacological targeting of PRRs	81
4. Perspectives/Conclusions	94
References	96

4. Glycosylation changes in inflammatory diseases 111

Sophie Groux-Degroote, Sumeyye Cavdarli, Kenji Uchimura,
Fabrice Allain, and Philippe Delannoy

1. Introduction	112
2. O-glycosylation changes in chronic inflammation	113
3. Glycosaminoglycans in inflammation	122
4. Crosstalk between gangliosides and inflammation in neurodegenerative diseases	134
5. Perspectives in therapeutic applications	140
References	141

5. Inflammatory bowel disease and targeted oral anti-TNF α therapy 157

Owen R. Griffiths, John Landon, Ruth E. Coxon, Keith Morris,
Philip James, and Rachel Adams

1. Immunotherapy	158
2. Inflammatory bowel disease	160
3. The gastrointestinal tract	163
4. Tumor necrosis factor-alpha (TNF α)	170
5. Future therapy	177
6. Conclusion	188
References	189

6. Interplay between inflammation and cancer 199

Rekha Khandia and Ashok Munjal

1. Introduction	200
2. Infectious inflammatory mediators	201
3. Roles of C-reactive protein (CRP) and serum amyloid A (SAA)	204
4. Inflammatory microenvironment association with cancer	205
5. Utility of anti-inflammatory drugs against cancer	231
6. Outlook	235
Acknowledgments	235
References	236

7. Microglial NLRP3 inflammasome activation in multiple sclerosis 247

Melis Olcum, Bora Tastan, Cagla Kiser, Sermin Genc, and Kursad Genc

List of Abbreviations	248
1. Multiple sclerosis	250
2. Animal models	253

3. Immunopathogenesis	254
4. Microglia	257
5. Microglia in EAE and MS	261
6. NLRP3 inflammasome	262
7. NLRP3 in CNS disorders	269
8. Microglial NLRP3 in EAE	270
9. Experimental therapeutic implications	277
10. NLRP3 in MS	288
11. Future perspective	294
Acknowledgments	295
References	295

8. Sleep deprivation, oxidative stress and inflammation 309

Fatin Atrooz and Samina Salim

1. Introduction	310
2. Sleep physiology	310
3. Sleep and mental health	313
4. Consequences of sleep deprivation	314
5. Sleep deprivation in children and adolescents	318
6. Neurobiological processes and early life sleep deprivation	319
7. Sleep deprivation and allostatic load	322
8. Sleep deprivation, oxidative stress and inflammation	322
References	328

Kamran Deste

Department of Neurosurgery, Istanbul Medipol University, Istanbul, Turkey
Health Campus, Istanbul, Turkey

Semra Genc

Immunobiology and Genomics Laboratory, Istanbul Medipol University, Istanbul, Turkey
Immunology Laboratory, Istanbul Medipol University, Istanbul, Turkey
Etil University Health Campus, Istanbul, Turkey
Institute of Health and Science, Istanbul Medipol University, Istanbul, Turkey

Owen R. Griffiths

Micropharmin Ltd, Clontarf, Dublin, Ireland
Micropharmin University, Clontarf, Dublin, Ireland